Concordance for ATRX (89%) was similar to numbers reported in the literature, where one study reported a concordance of 84.6% in 78 tumor samples when comparing IHC to whole-exome sequencing (WES), which is a more comprehensive form of NGS.21 Like in ATRX, the concordance for EGFR amplification (95%) was similar to that in the literature, where a 92% concordance was reported in a study that was comparing FISH to WES. The gene discussed is ATRX; the disease is neoplasm.